ValenzaBio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $130M

ValenzaBio General Information

Description

Developer of an antibody therapy designed to provide safe and effective treatment options for patients with unmet needs. The company's therapies include several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells, enabling researchers to devise new treatment options for patients with autoimmune and inflammatory diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 6701 Democracy Boulevard
  • Suite 300
  • Bethesda, MD 20817
  • United States
+1 (212)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 6701 Democracy Boulevard
  • Suite 300
  • Bethesda, MD 20817
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ValenzaBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 04-Jan-2023 $130M Completed Generating Revenue
2. Early Stage VC (Series A) 09-Apr-2021 Completed Pre-Clinical Trials
1. Seed Round 27-Feb-2020 $14.5M $14.5M Completed Pre-Clinical Trials
To view ValenzaBio’s complete valuation and funding history, request access »

ValenzaBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view ValenzaBio’s complete cap table history, request access »

ValenzaBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an antibody therapy designed to provide safe and effective treatment options for patients with unmet needs.
Biotechnology
Bethesda, MD
10 As of 2021

San Francisco, CA
 

Madison, WI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ValenzaBio Competitors (41)

One of ValenzaBio’s 41 competitors is Pharmacyclics, a Venture Capital-Backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pharmacyclics Venture Capital-Backed San Francisco, CA
Centrose Venture Capital-Backed Madison, WI
Confo Therapeutics Venture Capital-Backed Ghent, Belgium
Vera Therapeutics Formerly VC-backed Brisbane, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 41 competitors. Get the full list »

ValenzaBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ValenzaBio Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fidelity Management & Research Company Asset Manager Minority
Ikarian Capital Hedge Fund Minority
Janus Henderson Investors Asset Manager Minority
Opaleye Hedge Fund Minority
Pierre Fabre Holding Company Minority
You’re viewing 5 of 6 investors. Get the full list »

ValenzaBio FAQs

  • When was ValenzaBio founded?

    ValenzaBio was founded in 2019.

  • Where is ValenzaBio headquartered?

    ValenzaBio is headquartered in Bethesda, MD.

  • What is the size of ValenzaBio?

    ValenzaBio has 10 total employees.

  • What industry is ValenzaBio in?

    ValenzaBio’s primary industry is Biotechnology.

  • Is ValenzaBio a private or public company?

    ValenzaBio is a Private company.

  • What is the current valuation of ValenzaBio?

    The current valuation of ValenzaBio is .

  • What is ValenzaBio’s current revenue?

    The current revenue for ValenzaBio is .

  • How much funding has ValenzaBio raised over time?

    ValenzaBio has raised $93.9M.

  • Who are ValenzaBio’s investors?

    Fidelity Management & Research Company, Ikarian Capital, Janus Henderson Investors, Opaleye, and Pierre Fabre are 5 of 6 investors who have invested in ValenzaBio.

  • Who are ValenzaBio’s competitors?

    Pharmacyclics, Centrose, Confo Therapeutics, Vera Therapeutics, and Inovio Pharmaceuticals are some of the 41 competitors of ValenzaBio.

  • When was ValenzaBio acquired?

    ValenzaBio was acquired on 04-Jan-2023.

  • Who acquired ValenzaBio?

    ValenzaBio was acquired by Acelyrin.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process